Article Text

Download PDFPDF

586 Phase II study of Telomelysin (OBP-301) in combination with pembrolizumab in gastroesophageal (GEA) adenocarcinoma
  1. Sandipto Sarkar1,
  2. Sahrish Khan1,
  3. Jennifer Rachel Eads2,
  4. Reem Sharaiha1,
  5. David Carr-Locke1,
  6. Lillian Chang1,
  7. Gregory Ginsberg2,
  8. Lisa DiCicco2,
  9. Luis Garcia-Marcano8,
  10. Erika Hissong3,
  11. Doron Betel2 and
  12. Manish Shah1,3
  1. 1Weill Cornell Medicine, New York, NY, USA
  2. 2University of Pennsylvania, Philadelphia, PA, USA
  3. 3New York-Presbyterian Hospital, New York, NY, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background OBP-301 is a novel, oncolytic adenovirus that incorporates the human telomerase reverse transcriptase promoter for replication selectivity. As a single agent, OBP-301 demonstrated immune responses and clinical activity in phase I studies. We examined OBP-301 in combination with pembrolizumab in a multicenter phase II study as a novel mechanism to improve immunotherapy in advanced gastric cancer.

Methods Eligible patients had advanced GEA, progressed on at least 2 lines of prior therapy. Patients received OBP-301 at 2x1012 viral particles via direct tumor injection every two weeks x 4 injections as well as pembrolizumab 200 mg IV every 3 weeks. The primary endpoint was objective response rate (ORR). The null hypothesis that the ORR is < 15% was tested against the Ha ORR >30%. We used a Simon two-stage design, requiring 3 or more responses in 18 patients in the first stage to proceed to stage two. The study was closed after successfully completing stage one of the Simon’s two stage design to formally examine OBP-301 + pembrolizumab in an immunotherapy (IO) refractory GEA population. Tissue was collected for single cell RNA Sequencing to examine the tumor immune microenvironment pre- and post-OBP-301 injections.

Results From May 2019 to Oct 2022, we enrolled 16 patients, median age 65 (range 43–81), male n=13. OBP-301 direct tumor injection was well tolerated, median OBP-301 injections 3 (range 1–5). Toxicity attributed to OBP-301 included grade 2–3 fatigue/weakness (37.5%), grade 2–3 fever (12.5%), grade 2–3 elevated liver function tests (12.5%). We observed 2 patients (13%) with a partial response and 1 patient with a complete response, thereby meeting the Simon two-stage threshold. The responses were durable; two patients are currently without evidence of disease and the 3rd patient received 16 months of therapy before progression (figure 1). One patient with brain metastases demonstrated regression of metastatic disease following progression on immunotherapy alone. All patients were mismatch repair proficient. Complete response was associated with delayed increase in CD8 cytotoxic T cells, based on single cell RNA Seq expression (figure 2).

Conclusions OBP-301 with pembrolizumab has encouraging activity in GEA, with durable responses and demonstration of activity in immunotherapy refractory disease. Longitudinal single cell RNA seq data of tumor microenvironment will be presented. A formal phase II study of OBP-301 + pembrolizumab in IO refractory GEA patients is underway.

Abstract 586 Figure 1

Duration on study and response

Abstract 586 Figure 2

Longitudinal changes in tumor immune microenvironment (Subject 01-005). Activated CD8 T cells dramatically increase at D57, indicating activation of antitumor immunity induced by OBP-301

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.